1. Home
  2. ELOX vs XLO Comparison

ELOX vs XLO Comparison

Compare ELOX & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eloxx Pharmaceuticals Inc. Common Stock

ELOX

Eloxx Pharmaceuticals Inc. Common Stock

N/A

Current Price

$15.31

Market Cap

60.3M

Sector

N/A

ML Signal

N/A

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$9.14

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELOX
XLO
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.3M
56.9M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
ELOX
XLO
Price
$15.31
$9.14
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $38.25
N/A
AVG Volume (30 Days)
★ 21.4K
7.6K
Earning Date
08-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 41.67
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 589.88
52 Week Low
$10.00
$0.46
52 Week High
$23.40
$9.90

Technical Indicators

Market Signals
Indicator
ELOX
XLO
Relative Strength Index (RSI) 44.16 47.69
Support Level $13.92 $8.63
Resistance Level $19.43 $9.15
Average True Range (ATR) 1.39 0.24
MACD -0.19 0.00
Stochastic Oscillator 23.89 5.41

Price Performance

Historical Comparison
ELOX
XLO

About ELOX Eloxx Pharmaceuticals Inc. Common Stock

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: